Artificial intelligence focus
Latest in AI
ReportCRISPR & Genomics: Turning Data into Confident Drug Discovery Decisions
Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.
InterviewPhysics-based modelling offers a new way to study drug targets
Australian start-up OmnigeniQ has demonstrated what it describes as the first deterministic, physics-based computation of a human protein in its native state.
InterviewFrom scientist to bioinformatician: how AI coding tools dissolved the activation energy barrier
A biotech CEO with decades of scientific experience but sporadic coding practice gained practical bioinformatics capabilities in six weeks using AI coding assistants.
Featured
Physics-based modelling offers a new way to study drug targets
Australian start-up OmnigeniQ has demonstrated what it describes as the first deterministic, physics-based computation of a human protein in its native state.
Rethinking drug discovery through transcription factor biology
Complex diseases rarely have single targets. By focusing on transcription factor activity and disease signatures, Scripta Therapeutics is taking a different approach to identifying the drivers of pathology.
Webinars
- Previous
- Next
Whitepapers
- Previous
- Next
More Artificial Intelligence
CRISPR & Genomics: Turning Data into Confident Drug Discovery Decisions
Early drug discovery has no shortage of genomic data, but confidence remains scarce. This report examines how CRISPR, functional genomics and human-relevant models are being applied to determine which signals matter, how they influence disease biology and which targets and strategies are worth pursuing.
Physics-based modelling offers a new way to study drug targets
Australian start-up OmnigeniQ has demonstrated what it describes as the first deterministic, physics-based computation of a human protein in its native state.
From scientist to bioinformatician: how AI coding tools dissolved the activation energy barrier
A biotech CEO with decades of scientific experience but sporadic coding practice gained practical bioinformatics capabilities in six weeks using AI coding assistants.
New AI-designed T-cell engager LGTX-101 to be presented at AACR in San Diego
LabGenius Therapeutics will present preclinical data for LGTX-101, its AI-designed Nectin-4 x CD3 T-cell engager, at AACR 2026 in San Diego.
ELRIG announces keynote speakers for Advances in Cell-based Screening 2026 in Gothenburg
ELRIG has announced the keynote speakers for its 2026 Advances in Cell-based Screening conference in Gothenburg, where scientists will gather to explore how human-first models, advanced cell biology and AI are changing the future of drug discovery.
Designing targeted assays for clinical success from the start
Why do some targeted assays move smoothly from discovery to clinical practice while others stall? The answer often lies in the earliest design decisions, where choices about samples, platforms and data determine what is possible later.
Light-driven chemistry offers faster, greener drug design
Scientists at the University of Cambridge have developed a light-powered method to modify complex drug molecules without toxic chemicals, enabling faster, cleaner and more efficient drug development.
New target found for glaucoma treatment
Scientists have discovered that specialised immune cells in the eye help keep its drainage system clear and regulate pressure, which could inform new treatments for glaucoma.
New AI tool could accelerate drug discovery and cut lab costs
Scientists have developed a machine learning system that can predict how complex chemical reactions will produce the correct molecular form for medicines.
How self-driving labs are changing drug development
Automation and artificial intelligence are changing how scientists design, test and refine new molecules. At the University of Toronto, Stuart R Green and the Acceleration Consortium are building a self-driving lab that could change the pace of early drug discovery.
International Women’s Day: digital pathology in early drug discovery
For International Women’s Day, Dr Amanda Hemmerich, Global Director of Digital Pathology & Innovation at IQVIA Laboratories, describes how digital pathology is being applied in early drug development and what it takes to build credibility in a multidisciplinary technical field.
New AI foundation model aims to speed up drug discovery
Insilico Medicine and Liquid AI have partnered to develop a lightweight artificial intelligence foundation model designed to support multiple stages of drug discovery.
Why most labs are not ready for AI: Cenevo shares what must change
Most labs want to use AI, but few have the digital foundations to support it. Cenevo’s leaders explain why progress is slow and what laboratories must fix before AI can deliver real value.
Drug discovery integration takes centre stage at SLAS Boston 2026
Drug discovery has no shortage of powerful technologies, but the challenge now is making them work together. At SLAS Boston 2026, researchers and technology developers revealed how laboratories are connecting the entire experimental pipeline.
Making immunotherapy safer and more accessible through continuous digital monitoring
Immunotherapies such as CAR-T are extending survival, yet reliance on inpatient monitoring for cytokine release syndrome continues to restrict access. This article explores how continuous digital monitoring and AI-driven analysis could enable safer outpatient delivery and support more scalable immunotherapy adoption.
Advancing drug discovery with reproducible, animal-free 3D systems
Lukas Gaats and his team at mo:re are using automation to bring consistency to 3D cell culture and move drug discovery beyond animal models. Read on to find out how.